f8k_090513.htm
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 30, 2013
CLEVELAND BIOLABS, INC.
(Exact name of registrant as specified in its charter)
|
DELAWARE
|
|
001-32954
|
|
20-0077155
|
|
(State of incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer Identification No.)
|
73 High Street
Buffalo, New York 14203
(Address of principal executive offices and zip code)
Registrant’s telephone number, including area code: (716) 849-6810
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
|
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
|
(b) On August 30, 2013, Michael Fonstein, Ph.D. stepped down from his position as President of Cleveland BioLabs, Inc. (the “Company”), effective as of August 31, 2013. The Company has recommended to the Board of Directors of its majority owned subsidiary, Panacela Labs, Inc., that Dr. Fonstein be appointed as the Chief Executive Officer and President of Panacela Labs, Inc.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Date: September 5, 2013
|
CLEVELAND BIOLABS, INC.
|
|
| |
|
|
|
| |
|
|
|
| |
By:
|
/s/ Yakov Kogan
|
|
| |
|
Yakov Kogan
|
|
| |
|
Chief Executive Officer
|
|